Real-World Outcomes of First-Line CDK4/6 Inhibitor Therapy in HR-Positive, HER2-Negative Metastatic Breast Cancer: Insights from Ho Chi Minh City Oncology Hospital, Vietnam
-
By
-
Thi Hong Duc Phan
-
Hoang Quy Nguyen
-
September 7, 2026